Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLFS BioLife Solutions	$21.95 -3.4%	$22.31	$19.10 ▼ $29.55	$1.09B	1.79	419,060 shs	266,696 shs
LQDA Liquidia Technologies	$14.09 -0.4%	$14.97	$8.26 ▼ $19.41	$1.21B	-0.01	1.29 million shs	1.47 million shs
PLSE Pulse Biosciences	$16.03 -6.4%	$16.32	$13.50 ▼ $25.00	$1.15B	1.56	177,267 shs	116,090 shs
SNWV Sanuwave Health	$34.78 -3.2%	$31.03	$5.17 ▼ $39.50	$307.40M	1.24	148,382 shs	49,131 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLFS BioLife Solutions	+1.75%	-2.32%	-4.98%	+3.74%	+17.66%
LQDA Liquidia Technologies	+4.97%	+15.56%	-5.54%	+5.05%	+13.20%
PLSE Pulse Biosciences	+5.74%	+15.71%	-1.27%	+6.73%	+15.21%
SNWV Sanuwave Health	-0.25%	+13.52%	+16.50%	+20.09%	+3,592,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BLFS BioLife Solutions	2.9128 of 5 stars	3.5	3.0	0.0	0.0	1.8	2.5	0.6
LQDA Liquidia Technologies	3.2628 of 5 stars	4.5	0.0	0.0	0.0	1.4	4.2	0.6
PLSE Pulse Biosciences	3.8984 of 5 stars	3.5	0.0	0.0	4.2	1.8	4.2	0.0
SNWV Sanuwave Health	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BLFS BioLife Solutions	3.00	Buy	$31.17	41.99% Upside
LQDA Liquidia Technologies	3.00	Buy	$26.89	90.84% Upside
PLSE Pulse Biosciences	3.00	Buy	$22.00	37.24% Upside
SNWV Sanuwave Health	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SNWV, BLFS, LQDA, and PLSE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/7/2025	PLSE Pulse Biosciences	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$22.00
6/12/2025	LQDA Liquidia Technologies	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$23.00 ➝ $25.00
6/11/2025	LQDA Liquidia Technologies	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$25.00 ➝ $23.00
6/2/2025	LQDA Liquidia Technologies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/28/2025	LQDA Liquidia Technologies	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$36.00 ➝ $37.00
5/28/2025	LQDA Liquidia Technologies	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$20.00 ➝ $23.00
5/28/2025	LQDA Liquidia Technologies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
5/28/2025	LQDA Liquidia Technologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$29.00 ➝ $35.00
5/27/2025	LQDA Liquidia Technologies	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/21/2025	LQDA Liquidia Technologies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00
5/19/2025	LQDA Liquidia Technologies	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Market Perform ➝ Underperform	$13.00

(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BLFS BioLife Solutions	$87.76M	11.96	$0.12 per share	182.27	$7.52 per share	2.92
LQDA Liquidia Technologies	$14M	86.04	N/A	N/A	$0.91 per share	15.48
PLSE Pulse Biosciences	$700K	1,540.48	N/A	N/A	$1.87 per share	8.57
SNWV Sanuwave Health	$36.19M	8.22	N/A	N/A	($1.49) per share	-23.34

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BLFS BioLife Solutions	-$20.18M	-$0.29	N/A	N/A	N/A	-11.81%	-0.66%	-0.58%	8/14/2025 (Estimated)
LQDA Liquidia Technologies	-$130.39M	-$1.58	N/A	N/A	N/A	-903.80%	-177.91%	-60.15%	8/6/2025 (Estimated)
PLSE Pulse Biosciences	-$53.58M	N/A	0.00	∞	N/A	N/A	-68.44%	-58.17%	8/14/2025 (Estimated)
SNWV Sanuwave Health	-$31.37M	-$4.56	N/A	∞	N/A	-89.86%	N/A	-145.76%	N/A

Latest SNWV, BLFS, LQDA, and PLSE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	LQDA Liquidia Technologies	-$0.43	N/A	N/A	N/A	$3.90 million	N/A
5/9/2025	Q1 2025	SNWV Sanuwave Health	N/A	-$0.66	N/A	-$0.66	N/A	$9.34 million
5/8/2025	Q1 2025	BLFS BioLife Solutions	-$0.03	$0.04	+$0.07	-$0.01	$22.22 million	$23.94 million
5/8/2025	Q1 2025	LQDA Liquidia Technologies	-$0.42	-$0.45	-$0.03	-$0.45	$3.23 million	$3.12 million
5/8/2025	Q1 2025	PLSE Pulse Biosciences	N/A	-$0.25	N/A	-$0.25	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BLFS BioLife Solutions	N/A	N/A	N/A	N/A	N/A
LQDA Liquidia Technologies	N/A	N/A	N/A	N/A	N/A
PLSE Pulse Biosciences	N/A	N/A	N/A	N/A	N/A
SNWV Sanuwave Health	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BLFS BioLife Solutions	0.01	4.73	3.74
LQDA Liquidia Technologies	2.08	2.93	2.91
PLSE Pulse Biosciences	N/A	15.58	15.58
SNWV Sanuwave Health	N/A	0.40	0.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BLFS BioLife Solutions	93.24%
LQDA Liquidia Technologies	64.54%
PLSE Pulse Biosciences	76.95%
SNWV Sanuwave Health	42.53%

Insider Ownership

Company	Insider Ownership
BLFS BioLife Solutions	2.20%
LQDA Liquidia Technologies	26.50%
PLSE Pulse Biosciences	71.50%
SNWV Sanuwave Health	36.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BLFS BioLife Solutions	440	47.84 million	46.46 million	Optionable
LQDA Liquidia Technologies	50	85.49 million	62.83 million	Optionable
PLSE Pulse Biosciences	140	67.27 million	19.17 million	Optionable
SNWV Sanuwave Health	40	8.56 million	5.43 million	N/A

SNWV, BLFS, LQDA, and PLSE Headlines

Recent News About These Companies

Sanuwave: High Growth Wound Care Tech Primed For A Breakout

June 11, 2025 | seekingalpha.com

Sanuwave Health Appoints Industry Veteran Dustin Libby as Executive Vice President of Commercial Operations

June 3, 2025 | globenewswire.com

SANUWAVE Health, Inc. (SNWV): A Bull Case Theory

May 29, 2025 | insidermonkey.com

Sanuwave Health Appoints Greg Bazar to Board of Directors

May 28, 2025 | globenewswire.com

Sanuwave Health Selected for Inclusion in Russell 2000Â® Index

May 28, 2025 | globenewswire.com

Insider Selling: SANUWAVE Health, Inc. (NASDAQ:SNWV) Insider Sells 3,639 Shares of Stock

May 17, 2025 | insidertrades.com

SANUWAVE Health, Inc. (SNWV) Q1 2025 Earnings Call Transcript

May 9, 2025 | seekingalpha.com

Sanuwave Announces Q1 FY2025 Financial Results

May 9, 2025 | globenewswire.com

Sanuwave Will Host a Conference Call on May 9, 2025 at 8:30 AM (ET) to Present Q1 2025 Financial Results

May 5, 2025 | globenewswire.com

SANUWAVE Health Announces Preliminary Revenue Results for the First Quarter 2025 (Ended March 31, 2025)

April 8, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNWV, BLFS, LQDA, and PLSE Company Descriptions

BioLife Solutions NASDAQ:BLFS

$21.95 -0.77 (-3.39%)

Closing price 04:00 PM Eastern

Extended Trading

$21.92 -0.02 (-0.11%)

As of 04:04 PM Eastern

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

Liquidia Technologies NASDAQ:LQDA

$14.09 -0.06 (-0.42%)

Closing price 04:00 PM Eastern

Extended Trading

$14.10 +0.01 (+0.06%)

As of 07:56 PM Eastern

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Pulse Biosciences NASDAQ:PLSE

$16.03 -1.09 (-6.37%)

Closing price 04:00 PM Eastern

Extended Trading

$16.37 +0.34 (+2.13%)

As of 07:21 PM Eastern

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.

Sanuwave Health NASDAQ:SNWV

$34.78 -1.15 (-3.20%)

As of 04:00 PM Eastern

SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time